Vaxcyte Inc
NASDAQ:PCVX

Watchlist Manager
Vaxcyte Inc Logo
Vaxcyte Inc
NASDAQ:PCVX
Watchlist
Price: 36.99 USD 6.29% Market Closed
Market Cap: 4.8B USD

EV/EBITDA
Enterprise Value to EBITDA

-7.6
Current
-11.7
Median
4.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-7.6
=
Enterprise Value
4.8B USD
/
EBITDA
-627m USD
EBITDA Growth EV/EBITDA to Growth
US
Vaxcyte Inc
NASDAQ:PCVX
Average EV/EBITDA: 15.4
Negative Multiple: -7.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 789.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -650.3 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-7.2
2-Years Forward
EV/EBITDA
-6.5
3-Years Forward
EV/EBITDA
-6.3